Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 421

1.

Erdheim-Chester disease presenting with chorea and mimicking IgG4-related disorder.

Miron G, Karni A, Faust-Soher A, Giladi N, Alroy H, Gadoth A.

Neurol Clin Pract. 2019 Dec;9(6):524-526. doi: 10.1212/CPJ.0000000000000617. No abstract available.

PMID:
32042499
2.

Repeated Intravenous Amantadine Infusions in Advanced Parkinsonism: Experience of a Large Movement Disorder Center.

Kestenbaum M, Abu Snineh M, Nussbaum T, Gadoth A, Rosenberg A, Hindi A, Zitser J, Thaler A, Giladi N, Gurevich T.

Isr Med Assoc J. 2019 Dec;12(21):812-816.

3.

What happens before the first step? A New Approach to Quantifying Gait Initiation Using a Wearable Sensor.

Gazit E, Buchman AS, Dawe R, Curran TA, Mirelman A, Giladi N, Hausdorff JM.

Gait Posture. 2020 Feb;76:128-135. doi: 10.1016/j.gaitpost.2019.11.007. Epub 2019 Nov 9.

PMID:
31760316
4.

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.

Simuni T, Uribe L, Cho HR, Caspell-Garcia C, Coffey CS, Siderowf A, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Tosun D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten SJ, Bressman S, Marek K; PPMI Investigators.

Lancet Neurol. 2020 Jan;19(1):71-80. doi: 10.1016/S1474-4422(19)30319-9. Epub 2019 Oct 31.

PMID:
31678032
5.

Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson's disease risk?

Goldstein O, Gana-Weisz M, Cohen-Avinoam D, Shiner T, Thaler A, Cedarbaum JM, John S, Lalioti M, Gurevich T, Bar-Shira A, Mirelman A, Giladi N, Orr-Urtreger A.

Mol Genet Metab. 2019 Dec;128(4):470-475. doi: 10.1016/j.ymgme.2019.10.001. Epub 2019 Oct 13.

PMID:
31662221
6.

Successful Negotiation of Anticipated and Unanticipated Obstacles in Young and Older Adults: Not All Is as Expected.

Eyal S, Kurz I, Mirelman A, Maidan I, Giladi N, Hausdorff JM.

Gerontology. 2019 Aug 28:1-10. doi: 10.1159/000502140. [Epub ahead of print]

PMID:
31461708
7.

A new approach to quantifying the EEG during walking: Initial evidence of gait related potentials and their changes with aging and dual tasking.

Maidan I, Patashov D, Shustak S, Fahoum F, Gazit E, Shapiro B, Levy A, Sosnik R, Giladi N, Hausdorff JM, Mirelman A.

Exp Gerontol. 2019 Oct 15;126:110709. doi: 10.1016/j.exger.2019.110709. Epub 2019 Aug 23.

PMID:
31449852
8.

Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.

Agalliu I, Ortega RA, Luciano MS, Mirelman A, Pont-Sunyer C, Brockmann K, Vilas D, Tolosa E, Berg D, Warø B, Glickman A, Raymond D, Inzelberg R, Ruiz-Martinez J, Mondragon E, Friedman E, Hassin-Baer S, Alcalay RN, Mejia-Santana H, Aasly J, Foroud T, Marder K, Giladi N, Bressman S, Saunders-Pullman R.

Mov Disord. 2019 Sep;34(9):1392-1398. doi: 10.1002/mds.27807. Epub 2019 Jul 26.

9.

The Modifying Effect of Age on Survival in Parkinson's Disease: A Population-Based Cohort Study.

Peretz C, Rozani V, Giladi N, El-Ad B, Tsamir J, Hemo B, Gurevich T.

Neuroepidemiology. 2019;53(1-2):13-19. doi: 10.1159/000492672. Epub 2019 Jun 14.

PMID:
31203291
10.

Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill®) in Parkinson's disease.

LeWitt PA, Giladi N, Navon N.

Parkinsonism Relat Disord. 2019 Aug;65:131-138. doi: 10.1016/j.parkreldis.2019.05.032. Epub 2019 May 22.

PMID:
31176632
11.

Hierarchical Data-Driven Analysis of Clinical Symptoms Among Patients With Parkinson's Disease.

Kozlovski T, Mitelpunkt A, Thaler A, Gurevich T, Orr-Urtreger A, Gana-Weisz M, Shachar N, Galili T, Marcus-Kalish M, Bressman S, Marder K, Giladi N, Benjamini Y, Mirelman A.

Front Neurol. 2019 May 21;10:531. doi: 10.3389/fneur.2019.00531. eCollection 2019.

12.

Using global team science to identify genetic parkinson's disease worldwide.

Vollstedt EJ, Kasten M, Klein C; MJFF Global Genetic Parkinson's Disease Study Group.

Ann Neurol. 2019 Aug;86(2):153-157. doi: 10.1002/ana.25514. Epub 2019 Jun 26. No abstract available.

PMID:
31155756
13.

Using wearables to assess bradykinesia and rigidity in patients with Parkinson's disease: a focused, narrative review of the literature.

Teshuva I, Hillel I, Gazit E, Giladi N, Mirelman A, Hausdorff JM.

J Neural Transm (Vienna). 2019 Jun;126(6):699-710. doi: 10.1007/s00702-019-02017-9. Epub 2019 May 22. Review.

PMID:
31115669
14.

Is every-day walking in older adults more analogous to dual-task walking or to usual walking? Elucidating the gaps between gait performance in the lab and during 24/7 monitoring.

Hillel I, Gazit E, Nieuwboer A, Avanzino L, Rochester L, Cereatti A, Croce UD, Rikkert MO, Bloem BR, Pelosin E, Del Din S, Ginis P, Giladi N, Mirelman A, Hausdorff JM.

Eur Rev Aging Phys Act. 2019 May 3;16:6. doi: 10.1186/s11556-019-0214-5. eCollection 2019.

15.

Gait impairments in Parkinson's disease.

Mirelman A, Bonato P, Camicioli R, Ellis TD, Giladi N, Hamilton JL, Hass CJ, Hausdorff JM, Pelosin E, Almeida QJ.

Lancet Neurol. 2019 Jul;18(7):697-708. doi: 10.1016/S1474-4422(19)30044-4. Epub 2019 Apr 8. Review.

PMID:
30975519
16.

Anemia in men and increased Parkinson's disease risk: A population-based large scale cohort study.

Rozani V, Giladi N, Gurevich T, El-Ad B, Tsamir J, Hemo B, Peretz C.

Parkinsonism Relat Disord. 2019 Jul;64:90-96. doi: 10.1016/j.parkreldis.2019.03.010. Epub 2019 Mar 23.

PMID:
30922776
17.

Altered organization of the dorsal attention network is associated with freezing of gait in Parkinson's disease.

Maidan I, Jacob Y, Giladi N, Hausdorff JM, Mirelman A.

Parkinsonism Relat Disord. 2019 Jun;63:77-82. doi: 10.1016/j.parkreldis.2019.02.036. Epub 2019 Feb 23.

PMID:
30827838
18.

A Case with Beta-Propeller Protein Associated Neurodegeneration with Smooth Response to Levodopa Treatment.

Zitser J, Giladi N, Gurevich T.

Mov Disord Clin Pract. 2018 Mar 23;5(3):327-329. doi: 10.1002/mdc3.12604. eCollection 2018 May-Jun. No abstract available.

19.

Network abnormalities among non-manifesting Parkinson disease related LRRK2 mutation carriers.

Jacob Y, Rosenberg-Katz K, Gurevich T, Helmich RC, Bloem BR, Orr-Urtreger A, Giladi N, Mirelman A, Hendler T, Thaler A.

Hum Brain Mapp. 2019 Jun 1;40(8):2546-2555. doi: 10.1002/hbm.24543. Epub 2019 Feb 21.

PMID:
30793410
20.

Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).

Prakash N, Caspell-Garcia C, Coffey C, Siderowf A, Tanner CM, Kieburtz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, Chahine LM, Weintraub D, Casaceli C, Dorsey R, Wilson R, Herzog M, Daegele N, Arnedo V, Frasier M, Sherer T, Marek K, Frank S, Jennings D, Simuni T; Parkinson's Progression Markers InitiativeSteering Committee; Study Cores; Site Investigators; Coordinators; Industry and Scientific Advisory Board.

Parkinsonism Relat Disord. 2019 May;62:201-209. doi: 10.1016/j.parkreldis.2018.12.025. Epub 2019 Jan 31.

PMID:
30738748

Supplemental Content

Loading ...
Support Center